Abstract
Plants produce structurally and functionally diverse natural products. Some of these compounds possess promising health-benefiting properties, such as resveratrol (antioxidant) curcumin (anti-inflammatory, anti-allergic and anticancer), paclitaxel (anticancer) and artemisinin (antimalarial). These compounds are produced through particular biosynthetic pathways in the plants. While supply of these medicinally important molecules relies on extraction from the producing species, recent years have seen significant advances in metabolic engineering of microorganisms for the production of plant natural products. Escherichia coli and Saccharomyces cerevisiae are the two most widely used heterologous hosts for expression of enzymes and reconstitution of plant natural product biosynthetic pathways. Total biosynthesis of many plant polyketide natural products such as curcumin and piceatannol in microorganisms has been achieved. While the late biosynthetic steps of more complex molecules such as paclitaxel and artemisinin remain to be understood, reconstitution of their partial biosynthetic pathways and microbial production of key intermediates have been successful. This review covers recent advances in understanding and engineering the biosynthesis of plant polyketides and terpenoids in microbial hosts.
Keywords: Plant natural products, Polyketides, Terpenoids, Biosynthesis, Heterologous expression, Microorganisms, Metabolic Engineering
Current Topics in Medicinal Chemistry
Title:Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Volume: 16 Issue: 15
Author(s): Shuwei Zhang, Siyuan Wang and Jixun Zhan
Affiliation:
Keywords: Plant natural products, Polyketides, Terpenoids, Biosynthesis, Heterologous expression, Microorganisms, Metabolic Engineering
Abstract: Plants produce structurally and functionally diverse natural products. Some of these compounds possess promising health-benefiting properties, such as resveratrol (antioxidant) curcumin (anti-inflammatory, anti-allergic and anticancer), paclitaxel (anticancer) and artemisinin (antimalarial). These compounds are produced through particular biosynthetic pathways in the plants. While supply of these medicinally important molecules relies on extraction from the producing species, recent years have seen significant advances in metabolic engineering of microorganisms for the production of plant natural products. Escherichia coli and Saccharomyces cerevisiae are the two most widely used heterologous hosts for expression of enzymes and reconstitution of plant natural product biosynthetic pathways. Total biosynthesis of many plant polyketide natural products such as curcumin and piceatannol in microorganisms has been achieved. While the late biosynthetic steps of more complex molecules such as paclitaxel and artemisinin remain to be understood, reconstitution of their partial biosynthetic pathways and microbial production of key intermediates have been successful. This review covers recent advances in understanding and engineering the biosynthesis of plant polyketides and terpenoids in microbial hosts.
Export Options
About this article
Cite this article as:
Zhang Shuwei, Wang Siyuan and Zhan Jixun, Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms, Current Topics in Medicinal Chemistry 2016; 16 (15) . https://dx.doi.org/10.2174/1568026616666151012112637
DOI https://dx.doi.org/10.2174/1568026616666151012112637 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma
Current Topics in Medicinal Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Advancements in the Treatment and Repair of Tendon Injuries
Current Tissue Engineering (Discontinued) Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study
Current HIV Research Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy <i>In Silico</i> Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga
Current Pharmacogenomics and Personalized Medicine